ACSL4 and breast carcinoma: TRFC is a candidate marker of a subgroup of ER+/luminal-like breast cancer with poor outcome and tamoxifen resistance; GPX4-ACSL4 DKO cells show marked resistance to ferroptosis; Siramesine and lapatinib combination increase intracellular iron and ROS levels, and initially induce ferroptosis